MUC1 and neoplasm: In our cervical cancer xenograft mouse model, co-administration of PTX with EGFR inhibitor erlotinib significantly prevented the tumor growth and relapse, which was associated with reduced expression of MUC1 and ABCB1, and diminished activity of EGFR.